Semaglutide

(Wegovy®)

Wegovy®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (subcutaneous; pre-filled, single-dose pen that delivers doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg)
Drug ClassGlucagon-like peptide 1 (GLP-1) receptor agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
  • Indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and in adults with overweight in the presence of at least one weight-related comorbid condition.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Semaglutide (Wegovy) is indicated for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. It is also utilized to reduce excess body weight and maintain long-term weight reduction in adults, as well as pediatric patients aged 12 years and older with obesity.
  • The information was derived from a total of 19 systematic review/meta-analysis documents related to Wegovy (Semaglutide).
  • Semaglutide has demonstrated significant effectiveness in reducing body weight, BMI, and waist circumference across various studies. When compared to other GLP-1 receptor agonists (GLP-1 RAs), it frequently emerged as the most effective among them.
  • In terms of safety profile, gastrointestinal side effects were common, but serious adverse events did not differ significantly between Semaglutide and comparators, indicating an acceptable safety profile.
  • Evidence suggests that this drug is effective across various subgroups including adults with/without type 2 diabetes along with pediatric populations. However, there is an evidence gap for children regarding long-term outcomes and weight maintenance.
  • Combination therapies involving Semaglutide have been emphasized for achieving better results, underlining the importance of dosage considerations in treatment effectiveness.
  • Semaglutide ranked highly when compared to other treatments available for obesity, particularly at a dose of 2.4 mg, suggesting its viability as a non-surgical option against bariatric surgery.
  • The role of Semaglutide remains less explored during the transitioning phase from intensive medical treatment, especially concerning mental health recovery and obesity-related comorbidities, despite strong support towards its use based on current evidence.

Product Monograph / Prescribing Information

Document TitleYearSource
Wegovy (semaglutide injection) Prescribing Information2024Novo Nordisk

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Pharmacological interventions for the management of children and adolescents living with obesity—An update of a Cochrane systematic review with meta-analyses2024Pediatric Obesity
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis2024Biomedicine & Pharmacotherapy
Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis.2024Endocrine Practice
Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.2023Frontiers in Endocrinology
The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials.2023The American Journal of Clinical Nutrition
Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity.2023European Journal of Preventive Cardiology
Pharmaceutical therapies for the treatment of obesity: a network meta-analysis.2023Clinical Therapeutics
Clinical outcomes associated with drugs for obesity and overweight: a systematic review and network meta-analysis of randomized controlled trials.2023Diabetes, Obesity and Metabolism
Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review.2023Internal Medicine Journal
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.2023BMJ Open
Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. 2022Obesity Reviews
Efficacy of semaglutide in treating obesity: a systematic review of randomized controlled trials (RCTs).2022Cureus
Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis.2022International Journal of Clinical Pharmacy
Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review.2022Therapeutic Advances in Chronic Disease
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials.2022Frontiers in Pharmacology
The antiobesity effect and safety of glp-1 receptor agonist in overweight/obese patients without diabetes: a systematic review and meta-analysis.2022Hormone and Metabolic Research
Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta-analysis of randomized control trials.2022Obesity Reviews
Semaglutide 2.4 mg for the management of overweight and obesity: systematic literature review and meta-analysis.2022Diabetes, Metabolic Syndrome and Obesity
Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review.2022Clinical Epidemiology
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.2021The Lancet

Clinical Practice Guidelines